The the Swiss drugmaker will face off in the obesity area with leaders Novo Nordisk A/S and Indianapolis-based Eli Lilly and ...

Basel, Switzerland and Vacaville, US, 1 October 2024 – Lonza, one of the world’s largest healthcare development and manufacturing organizations, today announced it has completed its acquisition of the ...

The Temperature-Activated Generation of Signal (TAGS) technology was developed by Roche for its high-throughput PCR-based instruments.

Roche said it plans to focus on five key therapeutic areas as part of its new pharma strategy through 2030. The company will prioritize work in the areas of neurology, oncology and hematology, ...

(RTTNews) - Swiss drug major Roche Group (RHHBY), at its Pharma Day 2024, said it expects sales momentum to continue into 2025, with strong growth by both divisions of Pharma and Diagnostics. The ...

Neporrhoids certainly has one of the more interesting show starts of the Fringe. Roche kneels in front of a keyboard on the ...

Roche is narrowing its pipeline to 11 disease areas and continuing to invest in a targeted way, said Teresa Graham, chief ...

Roche presented early-stage data on its obesity injection and pill at EASD. Meanwhile, Oura enters into metabolic health ...

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. Roche raised hopes this year that it had a future blockbuster drug on its hands after early trial results ...

When Roche's Genentech gained approval for Ocrevus in 2017, the first-in-class infused drug quickly became the best-selling treatment in a crowded multiple sclerosis (MS) market. Three years later ...